The CBLB Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-mediated gene-disrupted polyclonal population derived from the HAP1 near-haploid myeloid leukemia cell line. This product provides a mixed knockout cell pool with targeted disruption of the CBLB gene, enabling loss-of-function studies of the encoded E3 ubiquitin-protein ligase.
HAP1 cells are a fibroblast-like, near-haploid human cell line originally derived from the KBM-7 chronic myelogenous leukemia line, widely employed as a simplified genetic model due to their haploid karyotype, which facilitates gene-editing and phenotypic analysis.
CBLB encodes a RING-type E3 ubiquitin-protein ligase that functions as a critical negative regulator of immune receptor signaling. In T cells, CBLB is activated downstream of TCR/CD28 co-stimulation and IL-2 signaling, and it targets key signaling mediators such as the p85 subunit of PI3K, PLC??1, VAV, and ZAP-70 for ubiquitin-mediated degradation or inactivation. CBLB interacts with adaptor proteins including GRB2, CRKL, CIN85, and various SH3 domain-containing proteins, thereby attenuating signal transduction through the TCR complex and CD28 co-receptor pathway.
In the HAP1 near-haploid background, CBLB knockout allows for unambiguous dissection of ubiquitin ligase activity and its impact on signaling networks without the complexity of diploid gene redundancy. Although HAP1 is myeloid in origin, it retains core signaling modules responsive to growth factors and cytokines, making it a tractable system to analyze CBLB-dependent regulation of PI3K/AKT and MAPK pathways, which are relevant to immune cell function and oncogenic signaling.
This polyclonal CBLB knockout cell population is well-suited for studying T cell receptor signaling modulation, immune checkpoint regulation, and autoimmune disease mechanisms. Researchers can employ these cells in ubiquitination assays, co-immunoprecipitation to assess CBLB?Csubstrate interactions, and western blotting to evaluate downstream signaling events. The knockout model can also be used in cytokine secretion and proliferation assays upon reconstitution with relevant receptors, or as a comparator in cancer immunotherapy research exploring CBLB??s role in immune evasion. For further details or technical support, please contact Ascent Research.
